
 
 
 
 
 
 
 
 
   
 1. A composition comprising at least one of the strains selected from Lactobacillus plantarum 2828 (ECGC 13110403); Lactobacillus plantarum 2830 (ECGC 13110402); and Lactobacillus plantarum 2691 (ECGC 13110401), or mutant 
 5 strains thereof. 
 
     
 2. A composition as claimed in claim 1, wherein the composition comprises two or more of the strains. 
 
     
 3. A composition as claimed in claim 1 or 2, wherein the composition further comprises the strain Lactobacillus acidophilus ATCC 43121 or a mutant strain 
 10 thereof. 
 
     
 4. A composition as claimed in any preceding claim, wherein the strain or strains is/are in an amount in the range of 10 5  cfu/g to 10 12  cfu/g. 
 
     
 5. A composition as claimed in any preceding claim, wherein the composition is encapsulated. 
 15 6. A composition as claimed in any preceding claim, wherein the strain or strains is/are mixed with a prebiotic and optionally, wherein the prebiotic comprises a prebiotic specific for the growth of the strain or strains. 
 7. A composition as claimed in any preceding claim, wherein the composition is in the form of a food stuffor a dietary supplement. 
 20 8. A composition according to any one of claims 1 to 7 for use in modifying the absorption of cholesterol. 
 9. A composition according to any one of claims 1 to 7 for use in the treatment of high cholesterol, heart disease, diabetes or obesity. 
 2014345342 08 Aug 2018 
 10. A method of treating an individual with elevated cholesterol serum levels by administering a composition having an effective amount of at least one ofthe strains selected from Lactobacillus plantarum 2828 (ECGC 13110403); Lactobacillus plantarum 2830 (ECGC 13110402); and Lactobacillus plantarum 
 5 2691 (ECGC 13110401), or mutant strains thereof. 
 11. A method of treating an individual with high cholesterol, heart disease, diabtetes or obesity by administering a composition having an effective amount of at least one of the strains selected from Lactobacillus plantarum 2828 (ECGC 13110403); Lactobacillus plantarum 2830 (ECGC 13110402); and Lactobacillus 
 10 plantarum 2691 (ECGC 13110401), or mutant strains thereof. 
 12. A method as claimed in claim 10 or 11, wherein the method comprises administering two or more of the strains. 
 13. A method as claimed in any one of claims 10 to 12, wherein the method further comprises additionaly administering the strain Lactobacillus acidophilus ATCC 
 15 43121 or a mutant strain thereof. 
 14. A method as claimed in any one of claims 10 to 13, wherein the strain or strains is/are administered in an amount in the range of 10 5  cfu/g to 10 12  cfu/g. 
 15. A method as claimed in any one of claims 10 to 14, wherein the strain or strains is/are mixed with a prebiotic and optionally, wherein the prebiotic comprises a 
 20 prebiotic specific for the growth of the strain or strains. 
 16. A method as claimed in one of claims 10 to 15, wherein the composition is in the form of a food stuff or a dietary supplement. 
 17. A dose of at least one of the strains selected from Lactobacillus plantarum (ECGC 13110403); Lactobacillus plantarum 2830 (ECGC 13110402); and 
 25 Lactobacillus plantarum 2691 (ECGC 13110401), or mutant strains thereof for 
 2014345342 08 Aug 2018 use in modifying the absorption of cholesterol, and wherein the dose comprises the strain or strains in a range of 10 5 cfu/g to 10 12 cfu/g. 
 18. A dose of at least one of the strains selected from Lactobacillus plantarum (ECGC 13110403); Lactobacillus plantarum 2830 (ECGC 13110402); and 
 5 Lactobacillus plantarum 2691 (ECGC 13110401), or mutant strains thereof for use in the treatment of high cholesterol, heart disease, diabetes or obesity, and wherein the dose comprises the strain or strains in a range of 10 5 cfu/g to 10 12  cfu/g. 
 19. A dose according to claim 17 or 18 comprising two or more of the strains. 
 10 20. A dose according to any one of claims 17 to 19, further comprising the strain 
 Lactobacillus acidophilus ATCC 43121 or a mutant strain thereof. 
 WO 2015/067947 
 PCT/GB2014/053301 
 1 /9 
 FIG. 1 
 SUBSTITUTE SHEET (RULE 26) 
 WO 2015/067947 
 PCT/GB2014/053301 
 2/9 c\i 
 O 
 
 
 
   
 
< 
 
< 
 
< 
   
 
CO 
 
o 
 
O 
   
 
QC 
 
Q 
 
Q 
   
 
 
 
O 
 
1— 
   
 
 
 
 
 
 
   
 
 
 
LO 
 
LO 
   
 
 
 
O 
 
o 
   
 
 
 
+ 
 
+ 
   
 
 
 
< 
 
< 
   
 
 
 
CO 
 
CO 
   
 
 
 
QC 
 
QC 
   
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
   
 
ω 
 
ω 
   
 
 
 
 
   
 
X 
 
X 
   
 
Ο 
 
Ο 
   
 
sO 
 
 
   
 
ο·' 
 
Ο - ' 
   
 
LO 
 
Ο 
   
 
<O 
 
CN 
   
 
+ 
 
+ 
   
 
< 
 
< 
   
 
CO 
 
CO 
   
 
Οί 
 
Οί 
   
 
 
 
 
   
 
 
 
 
 
 SUBSTITUTE SHEET (RULE 26) 
 WO 2015/067947 
 PCT/GB2014/053301 
 3/9 
 CO d 
 CC 
 
 
 
   
 
< 
 
< 
 
< 
 
co 
 
co 
   
 
CO 
 
o 
 
o 
 
 
 
 
   
 
CC 
 
Q 
 
Q 
 
X 
 
X 
   
 
 
 
o 
 
1— 
 
Ο 
 
Ο 
   
 
 
 
 
 
 
 
κΌ 
 
sO 
   
 
 
 
 
 
o— 
 
ο·' 
 
Ο - ' 
   
 
 
 
LO 
 
LO 
 
LO 
 
Ο 
   
 
 
 
CL> 
 
o 
 
<O 
 
CN 
   
 
 
 
+ 
 
+ 
 
+ 
 
+ 
   
 
 
 
<£ 
 
< 
 
< 
 
< 
   
 
 
 
C/3 
 
CO 
 
CO 
 
CO 
   
 
 
 
CC 
 
CC 
 
Οί 
 
oi 
   
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 SUBSTITUTE SHEET (RULE 26) 
 WO 2015/067947 
 PCT/GB2014/053301 
 4/9 
 SUBSTITUTE SHEET (RULE 26) 
 WO 2015/067947 
 PCT/GB2014/053301 
 5/9 
 Cholesterol reduction in % compared to control 
 FIG. 5 
 SUBSTITUTE SHEET (RULE 26) 
 WO 2015/067947 
 PCT/GB2014/053301 
 
     
 6/9 mg cholesterol reduction per OD 
 FIG. 6 
 SUBSTITUTE SHEET (RULE 26) 
 WO 2015/067947 
 PCT/GB2014/053301 
 
     
 7/9 
 Cellcount (CFU/g powder) 
 Powder counts 
 FIG. 7 
 Freeze drying survival 
 FIG. 8 
 SUBSTITUTE SHEET (RULE 26) 
 WO 2015/067947 
 PCT/GB2014/053301 
 
     
 8/9 
 Conversion rate Reduction in viability (μΜ/hr/el Ocells) (Log(CFU/mL)) 
 FIG. 10 
 Bile salt hydrolase activity (200μΜ GDC) 
 FIG. 11 
 SUBSTITUTE SHEET (RULE 26) 
 WO 2015/067947 
 PCT/GB2014/053301 
 
     
 9/9 
 Bile salt hydrolase activity (Oxgal) ρθμθΛίιοο ajejjsqns % 
 Bile salt conversion 
 SUBSTITUTE SHEET (RULE 26) 
 
   
 
 
 
 
 
 
 
 
